Details for Patent: 12,655,128
✉ Email this page to a colleague
Which drugs does patent 12,655,128 protect, and when does it expire?
Patent 12,655,128 protects GAVRETO and is included in one NDA.
This patent has forty-nine patent family members in thirty-five countries.
Drugs Protected by US Patent 12,655,128
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharms | GAVRETO | pralsetinib | CAPSULE;ORAL | 213721-001 | Sep 4, 2020 | RX | Yes | Yes | 12,655,128 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,655,128
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3371171 | ⤷ Start Trial | 122024000021 | Germany | ⤷ Start Trial |
| Argentina | 106548 | ⤷ Start Trial | |||
| Australia | 2016348402 | ⤷ Start Trial | |||
| Brazil | 112018008877 | ⤷ Start Trial | |||
| Canada | 3003721 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
